Sven Borchmann, MD, University of Cologne, Cologne, Germany, touches on the potential of circulating tumor DNA (ctDNA) and liquid biopsies as tools for monitoring response to treatment in patients with Hodgkin lymphoma (HL), as well as the next steps to better understand the role of these tools in stratifying patients response. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.